A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses

Authors: John H. Eldridge, Michael A. Egan, Demetrius Matassov, Stefan Hamm, Luz Hermida, Tracy Chen, Marc Tremblay, Susan Sciotto-Brown, Rong Xu, Antony Dimitrov, Emily R. Smith, Marc Gurwith, Robert T. Chen

Year: 2021

Journal: Vaccine

DOI: 10.xxxx/xxxxx or null

Summary

A protein vaccine for Nipah and Hendra viruses is under clinical evaluation in a Phase 1 study. The paper discusses the standardized template to describe key considerations for the benefit-risk assessment of this type of vaccine.

Key Findings

• The vaccine employs recombinant soluble Hendra glycoprotein (HeV-sG) adjuvanted with aluminum phosphate.
• The vaccine is under clinical evaluation in a Phase 1 study.

Methodology

• Study Type: Review

Topics

Vaccine, Protein, Safety, Benefit/Risk, Nipah, Hendra

Relevance

The paper discusses a standardized template to assess potential safety issues and understand the benefit-risk of protein vaccines, which may help improve public acceptance and communication of licensed protein vaccines.

Source

View the entire paper: File:1-s2.0-S0264410X21009075-main.pdf